I recently covered Cintas (CTAS) in this my September 24, 2025 post. The reason for revisiting CTAS so soon is to disclose that on November 3, 2025 I acquired an additional 100 shares @ ~$181.455 in a 'Side' account in the FFJ Portfolio. My total exposure is now 700 shares. On October 28, CTAS released [...]
I last reviewed Rollins (ROL) in this June 27, 2025 post in which I state: Rollins (ROL) may not appeal to some investors because the nature of its business is not 'sexy'. Sometimes, however, 'ho hum' businesses can offer investors the potential for very reasonable long-term total shareholder returns. Through its family of brands, ROL [...]
When I last reviewed Intercontinental Exchange (ICE) in this August 3, 2024 post, I concluded that shares were no longer undervalued. At the time of that post, ICE had just released its Q2 and YTD2024 results on August 1, 2024. I now revisit this existing holding given the release of Q3 and YTD2025 results on [...]
I last reviewed Thermo Fisher (TMO) in this July 24, 2025 post. In that post I express disappointment in the share price surge. The share price had risen to ~$475 at the July 24 market close yet as recently as July 7, 2025, I purchased 75 shares @ $421.9667 share in a 'Core' account in [...]
In my March 27, 2024 Automatic Data Processing (ADP) guest post at Dividend Power I conclude shares are overvalued. I have been an ADP shareholder for decades. The majority of my exposure is through a tax efficient Registered Retirement Savings Plan (RRSP) account for which I do not disclose details. I have made no additional [...]
In my July 26, 2025 CME Group Inc. (CME) post, I state that CME's Board authorized up to $3B in opportunistic share buybacks. On October 10, 2025, CME and S&P Global (SPGI) announced the completion of the sale of their 50/50 OSTTRA joint venture to KKR for ~$3.1B. Given these two events, I envision [...]
At the time of my February 6, 2025 post, Blackstone (BX) had just released its Q4 and FY2024 results. The company's outlook for FY2025 suggested it would be a year of robust results. Looking at BX's Press Releases, we see that it has been extremely active. Recently, BX announced that funds managed by BX [...]
I last reviewed Nasdaq (NDAQ) in this July 26, 2025 post at which time the most current financial information was for Q2 and YTD2025. With the release of Q3 2025 results on October 21, 2025, this is an opportune time to revisit this relatively small existing holding. Business Overview The best way to learn about [...]
When I last reviewed Moody's (MCO) in my April 27, 2025 post, I considered shares trading ~$437 to be close to my ~$450 fair value estimate. I, therefore, decided not to add to my exposure. Business conditions have improved subsequent to that review. With the October 22 release of Q3 and YTD2025 earnings and revised [...]
I last reviewed West Pharmaceutical (WST) in this July 25, 2025 post at which time I stated that the company's recovery appeared to 'be on track'. I concluded that very recent share price behavior suggested investors were warming up to WST. With shares trading hands at ~$279 and ~$280 being a what I deemed to [...]
